Arxada Posts Practice Statement Letter for Creditors
Basel, Switzerland – July 6, 2026 –
This is a notice to creditors of the Arxada group as follows:
Lenders under the senior facilities agreement dated 14 May 2021 between, among others, Herens Holdco S.à r.l. and the RCF / TLB lenders party thereto;
Holders of the USD 4.750% senior secured notes due 2028, issued by Herens Holdco S.à r.l;
Holders of the EUR 5.250% senior notes due 2029, issued by Herens Midco S.à r.l; and
holders of the USD floating rate notes due 2029, issued by Herens Midco S.à r.l,
together, the “Creditors”.
Herens UK Bidco Limited (the “Company”), on behalf of the Arxada group, hereby notifies all Creditors that a practice statement letter (the “Practice Statement Letter”) has been posted to: (i) the password-protected transaction website maintained by Kroll (the “Scheme Website”), and (ii) Arxada’s password-protected investor relations portal (the “Arxada Investor Portal”), in connection with the Company’s recapitalization and amend & extend transaction (the “A&E Transaction”).
The Company intends to implement the A&E Transaction by way of a scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme”). A hearing to consider and, if thought fit, approve the convening of creditor meetings in relation to the Scheme (the “Convening Hearing”) is expected to be held on July 27, 2026. The Practice Statement Letter sets out initial information about, among other things, the proposed Scheme, the proposed class composition of creditors for the purposes of the Scheme, and the Convening Hearing.
The Practice Statement Letter, which includes further detail relating to the Scheme and the A&E Transaction, is available at:
Arxada Investor Portal: https://www.debtdomain.com/
Scheme Website: https://deals.is.kroll.com/arxada
Creditors are encouraged to review the information on the Arxada Investor Portal and/or the Scheme Website.
If creditors have questions on the A&E Transaction, please email the Bain Capital, Cinven and/or Arxada at the contact details provided below.
Contact Information
Arxada
Peter Frauenknecht
cfo.arxada@arxada.com
Emily Johnson
emily.johnson@arxada.com
Bain Capital
Maria Andrisani
MAndrisani@BainCapital.com
Cinven
Christopher Anderson
Christopher.Anderson@Cinven.com
About Arxada
Arxada is a global leader in innovative solutions that protect our world. Our groundbreaking technologies, in-depth regulatory know-how, manufacturing and process development help our customers to safeguard nutrition, health and infrastructure efficiently through chemistry and microbiology that enhance sustainability. We offer a broad portfolio of ingredients and services for multiple end-markets that include Human Health & Nutrition, Home & Personal Care, Professional Hygiene, Paints & Coatings and Wood Protection. With customers in more than 100 countries, the company achieved sales of CHF 2billion in 2025. Headquartered in Basel (Switzerland), Arxada employs 3,100 associates across 24 production sites and 14 R&D centers, all committed to our customers’ success.
To learn more about Arxada, please visit: arxada.com and Arxada on LinkedIn.
Disclaimer
This release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities referred to in this announcement, in any jurisdiction, including the United States, in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, or an exemption from registration.
This announcement contains forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated timing of future announcements and the implementation the A&E Transaction. Forward-looking statements are based on our current expectations and assumptions and are subject to risks and uncertainties, many of which are outside our control, that could cause actual results or outcomes to differ materially from those expressed or implied in those statements. No assurance can be given that the matters described in these forward-looking statements will occur as described or at all. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.